FDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026)
FDA decision: Roflumilast (ARQ-151) by Arcutis Biotherapeutics (June 2026)
Chance
Full Approval
85%
▲ 62
Full Approval
85%
▲ 62
No Decision
8%
▼ 7
No Decision
8%
▼ 7
Denied (CRL Issued)
5%
▼ 16
Denied (CRL Issued)
5%
▼ 16
2 more
Market Rules
Full Approval
If the FDA's decision on Roflumilast (ARQ-151) by Arcutis Biotherapeutics in June 2026 is Full Approval before Jul 1, 2026, the market resolves to Yes. Outcome verified from AppliedXL.
Note: this event is mutually exclusive.
Timeline and payout
Market openJun 9, 2026 · 6:00pm EDT
Market closesAfter the outcome occurs
Projected payout30 minutes after closing
SeriesKXROFLUMILAST
EventKXROFLUMILAST-26
MarketKXROFLUMILAST-26-FA
Insider trading is prohibited
The following are prohibited from trading this contract:
- Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
- Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.